- freely available
Marine Drugs 2011, 9(9), 1502-1509; doi:10.3390/md9091502
Abstract: A new anthracene derivative, 3-hydroxy-1-keto-3-methyl-8-methoxy-1,2,3, 4-tetrahydro-benz[α]anthracene, was isolated from the marine strain Streptomyces sp. W007, and its structure was established by spectroscopic analysis including mass spectra, 1D- and 2D-NMR (1H–1H COSY, HMBC, HSQC and NOESY) experiments. 3-hydroxy-1-keto-3-methyl-8-methoxy-1,2,3,4-tetrahydro-benz[α]anthracene showed cytotoxicity against human lung adenocarcinoma cell line A549.
Natural products remain either the source or inspiration for a significant proportion of the new small-molecule chemical entities introduced as drugs . Microbial natural products are an important source of both existing and new drugs . Among the producers of commercially important metabolites, actinomycetes have proven to be a prolific source with a surprisingly small group of taxa accounting for the vast majority of compounds. Secondary metabolites produced by actinomycetes possess a wide range of biological activities [3–7], and the vast majority of these compounds are derived from the single genus Streptomyces .
Streptomyces species are distributed widely in marine habitats and are of commercial interest due to their unique capacity to produce novel metabolites. Our group has done research on novel natural products of marine Streptomyces species with potential antitumor activity for 12 years [9–12]. As part of this work, in our screening of marine Streptomyces isolates for more active secondary metabolites, a new anthracene derivative, 3-hydroxy-1-keto-3-methyl-8-methoxy-1,2,3,4-tetrahydro-benz[α]anthracene (compound 1) was obtained from the fermentation broth of marine Streptomyces sp. W007 for the first time. The structure of compound 1 was determined by LC-MS, 1H, 13C and 2D NMR spectroscopy and by comparison of the NMR data with other anthraquinone compounds, the cytotoxicities of compound 1 against human leukemic cells line HL-60, human lung adenocarcinoma cell line A549 and human hepatoma cell line BEL-7402 were studied, the details of structure and cytotoxicities of compound 1 are presented here.
2. Results and Discussion
2.1. Structure Analysis of Compound 1
Compound 1 (Figure 1, Table 1) was obtained as yellow powder and showed a quasi-molecular ion [M + H]+ at m/z 307 in the LC-MS, which was consistent with the molecular formula C20H18O3 (calcd for 306.3551), and required 12 degrees of unsaturation. Its 1H NMR spectrum exhibited an aliphatic methyl singlet at δH 1.46 (3H, s), one methoxy group at δH 4.09 (3H, s), two methylene signals at δH 3.35 (2H, dd, 15.0, 20.0 Hz) and δ 2.97 (2H, dd, 10, 15 Hz) and 7 aromatic proton signals at δH 10.10 (1H, s), 8.78 (1H, s), 8.26 (1H, d, 8.6 Hz), 7.65 (1H, d, 8.25 Hz), 7.45 (1H, t, 8.25, 7.45 Hz), 7.37 (1H, d, 8.6 Hz), 6.89 (1H, d, 7.55 Hz).
The 13C NMR, DEPT135 and HMBC spectra of compound 1 displayed two methyl resonances at δC 28.47 (C-13, 1-Me), 55.10 (C-14), two methylenes at δC 45.41 (C-4), 54.28 (C-2), methines at δC 135.19 (C-6), 127.37 (C-5), 102.5 (C-9), 125.17 (C-12), 121.52 (C-7), 121.13 (C-11), 126.35 (C-10), quaternary carbons at δC 155.38 (C-8), 145.61 (C-4a), 134.54 (C-11a), 130.69 (C-6a), 128.74 (C-12a), 125.46 (C-12b), 124.29 (C-7a,), 70.55 (C-3), in addition to one carbonyl at δC 198.76 (C-1). By detailed comparison of the 1H and 13C NMR data of compound 1 with 1,4,8,10-tetramethoxyanthracene-2-carbaldehyde , the similar NMR data of the aromatic moieties confirmed that compound 1 has the anthracene skeleton. Because compound 1 required 12 degrees of unsaturation, there is a six-carbon ring next to the anthracene skeleton. In the NOESY spectrum, the proton at δH 3.35 (H-4) showed a correlation with the proton at δH 7.37 (H-5) and the proton at δH 8.26 (H-6) showed a correlation with the proton at δH 8.78 (H-7). It confirmed the combination of the B, C and D rings, also implied carbonyl group was at position 1 not position 4. The methoxyl group at δH 4.09 (H-14) showed a NOE correlation with the proton at δH 6.89 (H-9). It indicated the combination of the A and B rings.
In the COSY spectra, δH 10.10 (1H, s) and δH 8.78 (1H, s) there is no correlation with other protons, they connected with C-12 (δC 125.17), C-7 (δC 121.52), respectively. The full assignment of compound 1 was supported by the HMBC correlations. The observed long range correlations from δH 1.46 (13-Me) to δC 145.61 (C-4a) and 198.76 (C-1) in the HMBC spectrum showed that a methyl group was attached to C-3, the HMBC correlation from δH 4.06 (OH, s) to δC 28.47 (C-13, 1-Me), 45.41 (C-4), 54.28 (C-2) and 70.55 (C-3) indicated that the hydroxyl group was attached to C-3. HMBC correlation from δH 4.09 (–O–CH3) to δC 155.38 (C-8) indicated that the methoxy group was attached to C-8. The HMBC correlation from δH 3.35 (H-4), 7.37 (H-5) and 2.97 (H-2) to δC 198.76 (C-1) indicated that a carbonyl unit was in C-1. As shown in Figure 1B, the linkage of the Six-carbon ring with the anthracene skeleton was established by the correlations from δH 3.35 (H-4) and 2.97 (H-2) to δC 145.61 (C-4a), δH 2.97 (H-2) to δC 125.46 (C-12b).
Consequently, the structure of compound 1 was established to be 3-hydroxy-1-keto-3-methyl-8- methoxy-1,2,3,4-tetrahydro-benz[α]anthracene (Table 1).
2.2. Cytotoxicity and Antifungal Activities
In the cytotoxicity test, compound 1 showed no cytotoxicity against human leukemic cells line HL-60 (Table 2), a weaker cytotoxicity against human hepatoma cell line BEL-7402 compared with adriamycin (Table 2). However, compound 1 exhibited a potent inhibitory activity against human lung adenocarcinoma cell line A549. Although compound 1 showed a weaker cytotoxicity at higher concentrations than the positive control, adriamycin, while at lower concentrations, the effect of compound 1 was found to be stronger than adriamycin (Table 2).
The results demonstrated that the compound 1 almost showed no antifungal activities against the Monilinia fructicola (Mf) and Colletotrichum lagenarium (Cl) (Table 3).
3. Experimental Section
3.1. General Experimental Procedures
NMR spectra were recorded on Bruker AVANCE III™ 500 spectrometers and TMS was used as internal standard. Column chromatography was carried out on silica gel (200–300 mesh) and Sephadex LH-20 (Amersham Biosciences, Uppsala, Sweden). LC-MS were obtained by ESI on a Thermo Fisher Scientific LCQ Fleet mass spectrometer. All reagents were of analytic grade.
Precoated silica gel plates (F-254, 0.2 mm) were used for analytical TLC. HPLC was performed on a JASCO PU-2087 HPLC apparatus with a Zorbax Eclipse XDB-C18 column (250 × 9.4 mm, 5 μm; 2 mL/min; 254 nm; Agilent, Palo Alto, CA, USA).
3.2. Strain and Medium for Isolation and Fermentation
Marine Streptomyces sp. W007 isolated on Gause’s synthetic agar containing 50% natural seawater was from the marine sediments of Kiaochow Bay, Qingdao. Marine Streptomyces sp. W007 was characterized according to the 16S rRNA gene sequence (Accession No. JN180126 in GenBank). Monilinia fructicola (Mf) and Colletotrichum lagenarium (Cl) were from Qingdao Agricultural University (Shandong, China).
Gause’s synthetic agar (for separation of streptomycete): soluble starch 20 g, KNO3 1 g, K2HPO4 0.5 g, MgSO4·7H2O 0.5 g, FeSO4·7H2O 0.01 g, K2Cr2O7 0.3 g, seawater 500 mL, deionized water 500 mL, pH 7.4. M2+ medium (for fermentation): malt extract 10 g, yeast extract 4 g, anhydrous glucose 4 g, deionized water 500 mL, seawater 500 mL, pH 7.8.
Well-grown agar cultures of Streptomyces sp. W007 were served to inoculate 1 L-Erlenmeyer flasks each containing 300 mL M2+ medium. The liquid medium of Streptomyces sp. W007 were incubated for 2 days with 180 rpm at 28 °C, then they were used to inoculate 100 Erlenmeyer flasks each containing 300 mL M2+ medium, inoculum size was 20% (v/v). At last, 100 Erlenmeyer flasks were held at 28 °C for 4 days (pH 7.8, 220 rpm).
3.4. Extraction and Separation
The culture broth (30 L) was filtered to give the mycelium and culture filtrate, and the filtrate was extracted by ethyl acetate. The mycelium was dried at 45 °C, and ultrasonically extracted three times by ethyl acetate and acetone respectively (15 min/time), then they were dried at 45 °C under reduced pressure. Three parts of organic layers were combined and defatted with cyclohexane to give a crude extract (8.4 g). The defatted extract was separated with silica gel column, five fractions were obtained. Fraction 1 was further purified by Sephadex LH-20 to afford A1–A5, A5 was purified by reverse column with a stepwise gradient of methanol/water (2:8–8:2) and detected by TLC to give four fractions (B1–B4). B4 was subjected to PTLC, during this step, three fractions (C1–C3) was obtained, C3 was separated by semi-preparative HPLC (JASCO PU-2087, Zorbax Eclipse XDB-C18, 250 × 9.4 mm; 2 mL/min; 254 nm; Agilent, Palo Alto, CA, USA) eluting with CH3OH/H2O(80:20, v/v) to afford compound 1 (retention time 9.37 min, 12 mg).
3.5. Cytotoxicity Tests and Antifungal Activities
Cytotoxic activity was evaluated using the human leukemic cell line HL-60 by the MTT (Methyl-Thiazol-Tetrozolium) method  and the human lung adenocarcinoma cell line A549 and human hepatoma cell line BEL-7402 by the SRB (sulforhodamine B) method . The antifungal activities of compound 1 were evaluated using the agar diffusion assay . Inhibition ratio was calculated according to the formula:
Asample: the absorbance of the sample at 540/515;
Ablank: the absorbance of the blank at 540/515.
In the MTT assay, the cell line was grown in RPMI-1640 supplemented with 10% FBS (Fetal bovine serum) under a humidified atmosphere of 5% CO2 and 95% air at 37 °C. Cell suspensions (200 μL) at a density of 5 × 104 cells/mL were plated in 96-well microtiter plates and incubated for 24 h. The compound 1 solutions (2 μL in MeOH) at different concentrations (0, 10−4, 10−5, 10−6, 10−7, 10−8 M) were added to each well and further incubated for 72 h under the same conditions. MTT solution (20 μL of a 5 mg/mL solution IPMI-1640 medium) was added to each well and incubated for 4 h. RPMI-1640 medium (150 μL) containing MTT was then gently replaced by DMSO (dimethyl sulfoxide) and pipetted to dissolve any formazan crystals formed. Absorbance was then determined on a Spectra Max Plus plate reader at 540 nm.
In the SRB assay, cell suspensions (200 μL) were plated in 96-cell plates at a density of 2 × 105 cells/mL. Then compound 1 solutions (2 μL in MeOH) at different concentrations (0, 10−4, 10−5, 10−6, 10−7, 10−8 M) were added to each well and further incubated for 24 h. Following drug exposure, the cells were fixed with 12% trichloroacetic acid and the cell layer was stained with 0.4% SRB. The absorbance of SRB solution was measured at 515 nm. Agar diffusion assay: compound 1 was dissolved in MeOH/CH2Cl2 (1:1) at concentrations of 5 μg/μL. Fifty microliters of each solution was pipetted onto a sterile filter disk, which was placed onto an appropriate agar growth medium for the respective test organism and subsequently sprayed with a suspension of the respective test organism. The disks (6 mm) were air-dried in bechtop, placed on an inoculated agar plate, and incubated at 28 °C overnight, the radius of the zone of inhibition was measured in mm.
The results of cytotoxic tests suggested that cytotoxicities of compound 1 are selective to the tested cell lines. Adriamycin plays an antitumor function: the interaction of adriamycin and type II DNA topoisomerase causes the DNA to break. Compound 1 showed a stronger cytotoxicity at low concentration, and weaker cytotoxicity at high concentration, than positive control adriamycin; such a phenomenon implied that antitumor mechanisms of adriamycin and compound 1 were different. Possible mechanisms for cytotoxic activity against human lung adenocarcinoma cell line A549 of compound 1 are as follows: compound 1 selectively induces apoptosis in human lung adenocarcinoma cell line A549 while sparing other cells; Compound 1 has negative effect on cancer cell proliferation and the cell cycle, maybe as an enzyme inhibitor; Compound 1 can inhibit metabolism of tumor cell lines and kill them.
Therefore, further studies on the bioactivity of compound 1 are being carried out and the results described in this study suggest that compound 1 could potentially lead to antitumor agents.
This work was supported by grants from CAS International Innovation Partnership Program: Typical Environmental Process and Effects on Resources in Coastal Zone Area, Outstanding young scholar fellowship of Shandong province (JQ200914), the National Natural Science Foundation of China (31000037) and the Knowledge Innovation Program of the Chinese Academy of Sciences (KSCX2-YW-G-073, KZCX2-YW-216, KZCX2-YW-209).
- Samples Availability: Available from the authors.
- Newman, DJ; Cragg, GM; Snader, KM. Natural Products as sources of new drugs over the period 1981–2002. J. Nat. Prod 2003, 66, 1022–1037. [Google Scholar]
- Solanki, R; Khanna, M; Lal, R. Bioactive compounds from marine actinomycetes. Indian J. Microbiol 2008, 48, 410–431. [Google Scholar]
- Wu, SJ; Fotso, S; Li, F; Qin, S; Laatsch, H. Amorphane Sesquiterpenes from a Marine Streptomyces sp. J. Nat. Prod 2007, 70, 304–306. [Google Scholar]
- Williams, PG; Asolkar, RN; Kondratyuk, T; Pezzuto, JM; Jensen, PR; Fenical, W. Saliniketals A and B, Bicyclic Polyketides from the Marine Actinomycete Salinispora arenicola. J. Nat. Prod 2006, 70, 83–88. [Google Scholar]
- Sujatha, P; Bapi Raju, KVVSN; Ramana, T. Studies on a new marine streptomycete BT-408 producing polyketide antibiotic SBR-22 effective against methicillin resistant Staphylococcus aureus. Microbiol. Res 2005, 160, 119–126. [Google Scholar]
- Miller, ED; Kauffman, CA; Jensen, PR; Fenical, W. Piperazimycins: Cytotoxic Hexadepsipeptides from a Marine-Derived Bacterium of the Genus Streptomyces. J. Org. Chem 2006, 72, 323–330. [Google Scholar]
- Moore, BS; Trischman, JA; Seng, D; Kho, D; Jensen, PR; Fenical, W. Salinamides, antiinflammatory depsipeptides from a marine streptomycete. J. Org. Chem 1999, 64, 1145–1150. [Google Scholar]
- Dharmaraj, S. Marine Streptomyces as a novel source of bioactive substances. World J. Microbiol. Biotechnol 2010, 26, 2123–2139. [Google Scholar]
- Li, F; Maskey, RP; Qin, S; Sattler, I; Fiebig, HH; Maier, A; Zeeck, A; Laatsch, H. Chinikomycins A and B: Isolation, structure elucidation, and biological activity of novel antibiotics from a marine Streptomyces sp. Isolate M045. J. Nat. Prod 2005, 68, 349–353. [Google Scholar]
- Maskey, RP; Li, FC; Song, Q; Fiebig, HH; Laatsch, H. Chandrananimycins A–C: Production of novel anticancer antibiotics from a marine Actinomadura sp. Isolate M048 by variation of medium composition and growth conditions. J. Antibiot 2003, 56, 622–629. [Google Scholar]
- Wu, SJ; Fotso, S; Li, F; Qin, S; Kelter, G; Fiebig, HH; Laatsch, H. N-carboxamido-staurosporine and selina-4(14),7(11)-diene-8,9-diol, new metabolites from a marine Streptomyces sp. J. Antibiot 2006, 59, 331–337. [Google Scholar]
- Ding, L; Pfoh, R; Ruhl, S; Qin, S; Laatsch, H. T-Muurolol sesquiterpenes from the marine Streptomyces sp. M491 and revision of the configuration of previously reported amorphanes. J. Nat. Prod 2008, 72, 99–101. [Google Scholar]
- Chiriboga, X; Gilardoni, G; Magnaghi, I; Finzi, PV; Zanoni, G; Vidari, G. New anthracene derivatives from Coussarea macrophylla. J. Nat. Prod 2003, 66, 905–909. [Google Scholar]
- Beekman, AC; Barentsen, ARW; Woerdenbag, HJ; van Uden, W; Pras, N; Konings, AWT; El-Feraly, FS; Galal, AM; Wikström, HV. Stereochemistry-dependent cytotoxicity of some artemisinin derivatives. J. Nat. Prod 1997, 60, 325–330. [Google Scholar]
- Iwasa, K; Moriyasu, M; Yamori, T; Turuo, T; Lee, DU; Wiegrebe, W. In vitro cytotoxicity of the protoberberine-type alkaloids. J. Nat. Prod 2001, 64, 896–898. [Google Scholar]
- Kouam, SF; Yapna, DB; Krohn, K; Ngadjui, BT; Ngoupayo, J; Choudhary, MI; Schulz, B. Antimicrobial prenylated anthracene derivatives from the leaves of Harungana madagascariensis. J. Nat. Prod 2007, 70, 600–603. [Google Scholar]
|Position||d (J in Hz)||δC|
|2||2.97 (2H, dd, 10, 15)||54.28|
|4||3.35 (2H, dd, 15.0, 20.0)||45.41|
|5||7.37 (1H, d, 8.6)||127.37|
|6||8.26 (1H, d, 8.6)||135.19|
|7||8.78 (1H, s)||121.52|
|9||6.89 (1H, d, 7.55)||102.5|
|10||7.45 (1H, t, 8.25, 7.45)||126.35|
|11||7.65 (1H, d, 8.25)||121.13|
|12||10.10 (1H, s)||125.17|
|13||1.46 (3H, s)||28.47|
|14||4.09 (3H, s)||55.10|
|Cancer cell line||Rate of inhibition of sample (%)||Concentration (M)
|human leukemic cells line HL-60||Rate of inhibition of compound 1||0||0||0||0||0|
|Rate of inhibition of adriamycin||100||88.5||89.5||88.2||0|
|human hepatoma cell line BEL-7402||Rate of inhibition of compound 1||37.5||37.0||25.7||19.5||0|
|Rate of inhibition of adriamycin||80.9||85.7||63.4||32.8||15.5|
|human lung adenocarcinoma cell line A549||Rate of inhibition of compound 1||65.5||62.8||61.8||47.8||48.8|
|Rate of inhibition of adriamycin||100||61.8||50.8||21.4||4.3|
|Microbial activities||The radius of the zone of inhibition (mm)|
© 2011 by the authors; licensee MDPI, Basel, Switzerland This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).